Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Histogen Inc. [CNAT]
Reports for Purchase
Showing records 41 - 60 ( 226 total )
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Healthcare - Yas'' Weekly Recap - What the Buy-side Reads
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Strong ENCORE-PH Data Encouraging; Though Primary Miss to Limit Stock Near-term; Adjusting PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
3Q Recap: All Eyes on ENCORE-PH Data; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Healthcare - AASLD Nonsense - Sense and the War of FXR Agonists
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Healthcare - The Liver Meeting Abstracts Part 1: Our Coverage Universe
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y